Atriva Therapeutics GmbH
General information
Atriva Therapeutics GmbH
Am Klopferspitz 19
Martinsried
82152 Planegg, Bavaria
Germany
Contact person: Christian M. Pangratz, Chief Executive Officer
Company main phone: +49 (69) 999916210
Website: https://www.atriva-therapeutics.com
Am Klopferspitz 19
Martinsried
82152 Planegg, Bavaria
Germany
Contact person: Christian M. Pangratz, Chief Executive Officer
Company main phone: +49 (69) 999916210
Website: https://www.atriva-therapeutics.com
| Year founded: | 2015 |
| Source of foundation: | Spin-off from university |
| Name of foundation source: | Universities of Giessen, Münster and Tübingen |
Corporate description / mission:
Atriva Therapeutics is a biopharmaceutical company developing host-cell-targeting antiviral and immunomodulatory therapies. The company aims to develop novel, highly efficacious, and safe therapies for the treatment of severe diseases caused by RNA viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza, respiratory syncytial virus infections, dengue fever, and hantavirus infections. Atriva Therapeutics' lead product zapnometinib is a novel, host-cell-targeting, orally available small-molecule drug inhibiting viral replication and rebalancing the body's immune response. The company will primarily focus resources on the development of zapnometinib for the treatment of patients hospitalized with severe influenza infections.
Atriva Therapeutics is a biopharmaceutical company developing host-cell-targeting antiviral and immunomodulatory therapies. The company aims to develop novel, highly efficacious, and safe therapies for the treatment of severe diseases caused by RNA viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza, respiratory syncytial virus infections, dengue fever, and hantavirus infections. Atriva Therapeutics' lead product zapnometinib is a novel, host-cell-targeting, orally available small-molecule drug inhibiting viral replication and rebalancing the body's immune response. The company will primarily focus resources on the development of zapnometinib for the treatment of patients hospitalized with severe influenza infections.
State of ownership: Private / independent
Headquarters: HQ: Yes
Headquarters: HQ: Yes
Remarks on ownership / listings
Ownership: Boutique Venture Funds, HTGF, Family Offices, founders and management
Ownership: Boutique Venture Funds, HTGF, Family Offices, founders and management
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
| Distribution: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 3 | |
| Phase I: | 1 | |
| Phase II: | 1 |
Description of products:
ATR-002
ATR-002
Special IP situation:
The company owns eleven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041
The company owns eleven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041
Technology used:
Atriva product platform is based on MEK kinase inhibitors focusing on severe viral infections and applicable for use with high-risk COVID-19 and influenza patients.
Atriva product platform is based on MEK kinase inhibitors focusing on severe viral infections and applicable for use with high-risk COVID-19 and influenza patients.
© 2025 Biotechgate by Venture Valuation